Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders |
| [02-June-2026] |
MILWAUKEE, June 2, 2026 /PRNewswire/ -- Ademi LLP is investigating Rallybio (Nasdaq: RLY) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avenzo Therapeutics.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Following closing, Rallybio equityholders are expected to own approximately 2.8% of the combined company, and Avenzo equityholders are expected to own approximately 97.2% of the combined company. Rallybio insiders will receive substantial benefits as part of change of control arrangements The transaction agreement unreasonably limits competing transactions for Rallybio by imposing a significant penalty if Rallybio accepts a competing bid. We are investigating the conduct of the Rallybio board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Ademi LLP
SOURCE Ademi LLP | ||
Company Codes: NASDAQ:RLY,NASDAQ-CM:RLYB |
View original content to download multimedia:
